Kappos L - Search Results

1

Genomics and proteomics: role in the management of multiple sclerosis.

Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, Sandbrink R, Lindberg RL. Kappos L, et al. J Neurol. 2005 Sep;252 Suppl 3:iii21-iii27. doi: 10.1007/s00415-005-2013-3. J Neurol. 2005. PMID: 16170496 Review.

2

Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial.

Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, Miltenburger C, Pozilli C. Polman CH, et al. Among authors: kappos l. Mult Scler. 1995;1 Suppl 1:S51-4. Mult Scler. 1995. PMID: 9345400 Clinical Trial.

3

Interferon beta in the treatment of multiple sclerosis--closing remarks.

Kappos L. Kappos L. Mult Scler. 1995;1 Suppl 1:S64-6. Mult Scler. 1995. PMID: 9345403 Review. No abstract available.

4

Combinations of drugs.

Kappos L. Kappos L. Mult Scler. 1996 Jul;1(6):400-3. doi: 10.1177/135245859600100624. Mult Scler. 1996. PMID: 9345426

5

Use of composite scores in the quantification of deterioration in multiple sclerosis.

Lienert C, Lechner-Scott J, Schött D, Constantinescu C, Kappos L. Lienert C, et al. Among authors: kappos l. Mult Scler. 1999 Aug;5(4):220-2. doi: 10.1177/135245859900500405. Mult Scler. 1999. PMID: 10467379 Review. No abstract available.

6

The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement.

Molyneux PD, Miller DH, Filippi M, Yousry T, Kappos L, Gasperini C, Adèr HJ, Barkhof F. Molyneux PD, et al. Among authors: kappos l. J Neurol. 2000 Jan;247(1):34-40. doi: 10.1007/s004150050007. J Neurol. 2000. PMID: 10701895

7

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group.

Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, Steinman L. Kappos L, et al. Nat Med. 2000 Oct;6(10):1176-82. doi: 10.1038/80525. Nat Med. 2000. PMID: 11017151 Clinical Trial.

8

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH. Molyneux PD, et al. Among authors: kappos l. Brain. 2000 Nov;123 ( Pt 11):2256-63. doi: 10.1093/brain/123.11.2256. Brain. 2000. PMID: 11050025 Clinical Trial.

9

The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis.

Lindberg RL, De Groot CJ, Montagne L, Freitag P, van der Valk P, Kappos L, Leppert D. Lindberg RL, et al. Among authors: kappos l. Brain. 2001 Sep;124(Pt 9):1743-53. doi: 10.1093/brain/124.9.1743. Brain. 2001. PMID: 11522577

10

Visual and motor evoked potentials in the course of multiple sclerosis.

Fuhr P, Borggrefe-Chappuis A, Schindler C, Kappos L. Fuhr P, et al. Among authors: kappos l. Brain. 2001 Nov;124(Pt 11):2162-8. doi: 10.1093/brain/124.11.2162. Brain. 2001. PMID: 11673318 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

810 results

Search Page

Filters